Trial Profile

A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Peptide vaccines (Primary) ; Peptide vaccines (Primary)
Indications Malignant melanoma; Uveal melanoma
Focus Adverse reactions; Pharmacodynamics
Acronyms Mel64

Most Recent Events

26 Mar 2020 Status changed from active, no longer recruiting to completed.
27 Jun 2019 Status changed from recruiting to active, no longer recruiting.
31 Oct 2018 Planned number of patients changed from 47 to 25.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com